Global Wealth Management Investment Advisory Inc. Raises Stake in Medtronic PLC $MDT

Global Wealth Management Investment Advisory Inc. increased its stake in Medtronic PLC (NYSE:MDT) by 26.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,862 shares of the medical technology company’s stock after purchasing an additional 9,182 shares during the quarter. Global Wealth Management Investment Advisory Inc.’s holdings in Medtronic were worth $4,177,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in MDT. Norges Bank purchased a new position in Medtronic in the second quarter valued at about $1,432,698,000. Vanguard Group Inc. grew its holdings in shares of Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after acquiring an additional 1,895,165 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in Medtronic by 332.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock valued at $130,300,000 after purchasing an additional 1,148,803 shares in the last quarter. Perkins Coie Trust Co raised its holdings in Medtronic by 2,952.2% during the second quarter. Perkins Coie Trust Co now owns 1,155,425 shares of the medical technology company’s stock worth $100,718,000 after purchasing an additional 1,117,570 shares during the last quarter. Finally, Laurel Wealth Advisors LLC boosted its position in Medtronic by 8,779.8% during the second quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock worth $93,243,000 after purchasing an additional 1,057,618 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on MDT. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, January 3rd. JPMorgan Chase & Co. lifted their target price on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Morgan Stanley increased their price target on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Royal Bank Of Canada raised their price objective on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Finally, Truist Financial reduced their target price on Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Trading Down 0.5%

Shares of MDT stock opened at $96.46 on Wednesday. The firm’s 50-day simple moving average is $98.56 and its 200-day simple moving average is $94.72. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The firm has a market cap of $123.67 billion, a P/E ratio of 26.00, a PEG ratio of 2.56 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be given a $0.71 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. Medtronic’s dividend payout ratio is presently 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).